Post TAVI LVEF Improvement: Only with No New Conduction Defects

Original title: Impact of a New Conduction Defect Alter Transcatheter Aortic Valve Implantation on Left Ventricular Function Reference: Rainer Hoffmann, et al. J Am Coll Cardiol Intv 2012;5:1257– 63.

TAVI development in high risk patients can produce new conduction defects and require a definitive pacemaker in almost a third of treated patients. 

The aim of this study was to evaluate the impact of new conduction defects after TAVI on left ventricular function at 1 year follow up. The prospective analysis included 90 consecutive patients between January 2009 and July 2010.

Implanted valves were Corevalve in 52 patients and Edwards SAPIENS in 38. LV volumes and ejection fraction were similar in both groups prior to procedure. New conduction defects presented in 39 patients, 31 of these patients presented left bundle branch block (12 finally requiring permanent pacing) and 8 patients presented complete AV block and definite pacemaker implantation. New conduction defects presented in 32 of the Core Valve implanted patients and 7 of those who received the Edwards SAPIENS valve.

Patients who did not present new conduction defects showed significant improvement of LVEF compared to baseline (5.8 ± 7.9%; p= 0.001) and end -systolic volume. In the group of patients that presented new conduction defects the LVEF practically did not show changes at 12 months. There was no difference in LVEF associated to the implanted valve. The presence of new conduction defects and baseline LVEF were predictors of reduced LVEF at 12 months.

Conclusion 

Ejection fraction after TAVI improves in those patients that do not present new conduction defects, this does not happen in patients that do present new conduction defects.

Editorial Comment:

Despite de fact that new conduction defects and permanent pacing requirements after TAVI are frequent, this does not necessarily translate into greater mortality, despite the ventricular function may see no improvement. Although surgery has brought less conduction defects, it has been performed in less complex patients compared to the ones treated with this technique; this may be contributing to new conduction defects. As regards valves, they will eventually require improvement in order to reduce such complications. 

Courtesy of Dr Carlos Fava,
Interventional Cardiologist,
Favaloro Foundation, Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation

Mitral regurgitation (MR) is a common condition, with approximately 3.5% prevalence in individuals under 65, increasing to 7.7% in those over 75. It can...

Is Angioplasty Always Necessary after TAVR?

Courtesy of: Silvina E. Gomez, MD The prevalence of coronary artery disease (CAD) in patients undergoing TAVR is high, ranging from 40 to 70%, according...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

ROLLER COASTR-EPIC22: Comparison of Plaque Modification Techniques in Severely Calcified Coronary Lesions

The presence of coronary calcium significantly limits the success of percutaneous coronary interventions (PCI), primarily due to suboptimal stent expansion. This can lead to...

Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation

Mitral regurgitation (MR) is a common condition, with approximately 3.5% prevalence in individuals under 65, increasing to 7.7% in those over 75. It can...